• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

    9/28/23 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email

    Conference Call Scheduled for today, September 28, 2023, at 5:00pm ET

    GARDNER, Mass., Sept. 28, 2023 /PRNewswire/ -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year ended June 30, 2023.

    Precision Optics Corporation Logo (PRNewsfoto/Precision Optics Corporation)

    FY 2023 Financial Highlights (Year Ended June 30, 2023):

    • Revenue increased 34% to $21.0 million, a new record, compared to $15.7 million in the previous fiscal year.
    • Production revenue reached a new annual record of $14.3 million, an increase of 39% compared to the previous fiscal year.
    • Engineering revenue was a record $6.7 million, an increase of 25% compared to the previous fiscal year.
    • Gross margin was 36.8% compared to 31.4% in the previous fiscal year.
    • Net loss was ($144,613) which compared to net loss of ($928,416) in the previous year.
    • Adjusted EBITDA, defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation and other income, was a record $491,219, compared to $(242,293) in the previous fiscal year. Adjusted EBITDA for fiscal 2023 included the impact of a one-time increase in the allowance for doubtful accounts of $464,000 for a single customer.

    Q4 2023 Financial Highlights (3 Months Ended June 30, 2023):

    • Revenue increased 5% to $5.02 million, compared to $4.79 million in the same quarter of the previous fiscal year.
    • Production revenue was $3.0 million compared to $3.1 million in the same quarter of the previous fiscal year.
    • Engineering revenue was $2.0 million compared to $1.7 million in the same quarter of the previous fiscal year.
    • Gross margin was 38.5% compared to 30.1% in the same quarter of the previous year.
    • Net loss for the quarter was ($96,125) which compared to net income of $269,293 in the same quarter of the previous year.  Net loss for the fourth quarter of fiscal 2023 was negatively impacted by the increase in the allowance for doubtful accounts discussed above.
    • Adjusted EBITDA was $(412,026) for the quarter compared to $237,153 in the same quarter of the previous year.  Adjusting for the one-time increase in the allowance for doubtful accounts, adjusted EBITDA would have been $ 51,974.

    Recent Additional Highlights:

    • In April 2023, the Company announced the receipt of an initial product development order for a next-generation urological endoscopy program totaling approximately $1.3 million from an established medical device company.
    • The Company has made a significant investment in its management team. In April 2023, appointed Mahesh Lawande in the newly created role of Chief Operating Officer of Precision Optics and in June appointed Wayne Coll as Chief Financial Officer
    • In May 2023, the Company announced the receipt of a follow-on product development order for a next generation single-use urology program totaling approximately $1.5 million from an established medical device company leveraging the Company's unique expertise in micro-optics, medical systems, and digital imaging.
    • In June 2023, the Company strengthened its balance sheet through a combination of three actions: A new $750,000 term loan with Main Street Bank; expansion of its line of credit facility to $1.25 million from $500,000; and the completion of a warrant-less common stock private placement providing $2.52 million in gross proceeds.

    Precision Optics' CEO, Joseph Forkey, commented, "Fiscal year 2023 was a year of tremendous progress for Precision Optics as we continued to leverage our unique technological and production capabilities to drive record revenues and positive Adjusted EBITDA. Our business model, where we apply our technical knowledge to support a customer from the early design phase all the way through mass manufacture, continues to show great signs of success. During fiscal year 2023, we achieved both record production revenue of $14.3 million and record engineering revenue of $6.7 million. Also, gross margins increased to 37% compared to 31% last fiscal year. We continue to increase our technical resources and to successfully attract new programs to our product development pipeline.  This pipeline is the strongest indicator of long-term revenue growth potential and expanded substantially in the fourth quarter as we scaled up efforts on several key programs that we expect to be long-term contributors to our business growth."

    "I am also very excited that the Company was able to attract Mahesh Lawande, Chief Operating Officer and Wayne Coll, Chief Financial Officer, both of whom have repeated experience in driving medical device technology companies to greater levels of efficiency, profitability and growth." 

    "Overall, I am pleased with the many accomplishments of fiscal year 2023. The company achieved record revenues, improved gross margins, and record Adjusted EBITDA. We have been delivering against significant customer programs and expect the pipeline of new projects to result in accelerated growth in the second half of Fiscal 2024."

    The following table summarizes the fourth quarter and fiscal year (unaudited) results for the periods ended June 30, 2023, and 2022:

    Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented.





    Three Months



    Fiscal Year





    Ended June 30,



    Ended June 30,





    2023

    2022



    2023

    2022

    Revenues

    $5,024,140

    $4,793,511

    $21,044,467

    $15,678,248















    Gross Profit

    1,934,945

    1,441,363



    7,734,136

    4,928,187















    Stock Compensation Expenses

    142,242

    150,377



    884,606

    800,473

    Business Acquisition Expenses

    ­-

    -



    -

    162,125

    Other

    2,398,177

    1,711,456



    7,488,618

    5,479,479

    Total Operating Expenses

    2,547,419

    1,861,833



    8,372,684

    6,442,077















    Operating Income (Loss)

    (612,475)

    (420,470)



    (638,548)

    (1,513,891)















    Net Income (Loss)

    (96,125)

    269,293



    (144,613)

    (928,416)















    Income (Loss) per Share













    Basic and Fully Diluted

    $(0.02)

    0.05



    $(0.03)

    $(0.18)















    Weighted Average Common Shares Outstanding













    Basic and Fully Diluted

    5,687,526

    5,295,720



    5,666,034

    5,295,720

    Conference Call Details

    Date and Time: Thursday, September 28, 2023, at 5:00pm ET

    Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or

    (412) 317-5705.

    Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/nKYp4AE46Pz.  

    Replay: A teleconference replay of the call will be available until October 5, 2023, at (877) 344-7529 or (412) 317-0088, replay access code 5811443. A webcast replay will be available at https://app.webinar.net/nKYp4AE46Pz.

    About Precision Optics Corporation

    Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture.  Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

    Non-GAAP Financial Measures

    Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation, restructuring and other acquisition-related items.

    This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

    Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

    About Forward-Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

    Company Contact: 

    PRECISION OPTICS CORPORATION

    22 East Broadway

    Gardner, Massachusetts 01440-3338

    Telephone: 978-630-1800

    Investor Contact:

    LYTHAM PARTNERS, LLC

    Robert Blum

    Telephone: 602-889-9700

    [email protected]

    Following are the Company's Consolidated Balance Sheets at June 30, 2023 and June 30, 2022, and Statements of Operations, for the three and twelve months ended June 30, 2023 and 2022:

     

    PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

    Consolidated Balance Sheets at June 30, 2023 and 2022

















    2023





    2022

    ASSETS















    Current Assets:















    Cash and cash equivalents



    $

    2,925,852





    $

    605,749

    Accounts receivable, net of allowance for doubtful accounts of $606,715

     at June 30, 2023 and $44,135 at June 30, 2022





    3,907,407







    2,663,872

    Inventories





    2,776,216







    3,022,147

    Prepaid expenses





    249,681







    213,448

    Total current assets





    9,859,156







    6,505,216

















    Fixed Assets:















    Machinery and equipment





    3,227,481







    3,215,412

    Leasehold improvements





    825,752







    843,903

    Furniture and fixtures





    242,865







    219,999

    Total fixed assets





    4,296,098







    4,279,314

    Less—Accumulated depreciation and amortization





    3,862,578







    3,651,843

    Net fixed assets





    433,520







    627,471

















    Operating lease right-to-use asset





    358,437







    517,725

    Patents, net





    265,111







    229,398

    Goodwill





    8,824,210







    8,824,210

















    TOTAL ASSETS



    $

    19,740,434





    $

    16,704,020

















    LIABILITIES AND STOCKHOLDERS' EQUITY















    Current Liabilities:















    Current portion of capital lease obligation



    $

    43,209





    $

    40,705

    Current maturities of long-term debt





    513,259







    367,714

    Current portion of acquisition earn out liability





    –







    166,667

    Accounts payable





    2,432,264







    2,239,175

    Customer advances





    1,174,690







    905,113

    Accrued compensation and other





    927,521







    716,702

    Operating lease liability





    168,677







    150,565

    Total current liabilities





    5,259,620







    4,586,641

















    Capital lease obligation, net of current portion





    68,482







    111,691

    Long-term debt, net of current maturities





    2,175,980







    1,961,141

    Acquisition earn out liability, net of current portion





    –







    705,892

    Operating lease liability, net of current portion





    189,760







    367,160

















    Stockholders' Equity:















    Common stock, $0.01 par value: 50,000,000 shares authorized; issued and

     outstanding – 6,066,518 shares at June 30, 2023 and 5,638,302 shares at June 30, 2022





    60,665







    56,383

    Additional paid-in capital





    60,224,934







    57,009,506

    Accumulated deficit





    (48,239,007)







    (48,094,394)

    Total stockholders' equity





    12,046,592







    8,971,495

















    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY



    $

    19,740,434





    $

    16,704,020

     

    PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

    Consolidated Statements of Operations

    for the Years Ended June 30, 2023 and 2022

















    2023





    2022













    Revenues



    $

    21,044,467





    $

    15,678,248

    Cost of goods sold





    13,310,331







    10,750,061

















    Gross profit





    7,734,136







    4,928,187

















    Research and development expenses, net





    992,375







    666,479

    Selling, general and administrative expenses





    7,380,309







    5,613,473

    Business acquisition expenses





    –







    162,125

    Total operating expenses





    8,372,684







    6,442,077

















    Operating loss





    (638,548)







    (1,513,890)

















    Other income (expense)















    Interest expense





    (218,927)







    (155,658)

    Gain on forgiveness of bank note





    –







    –

    Gain on revaluation of contingent earn-out liability





    714,798







    742,084

















    Loss before provision for income taxes





    (142,677)







    (927,464)

















    Provision for income taxes





    1,936







    952

















    Net loss



    $

    (144,613)





    $

    (928,416)

















    Loss per share:















    Basic and fully diluted



    $

    (0.03)





    $

    (0.18)

















    Weighted average common shares outstanding:















    Basic and fully diluted





    5,666,034







    5,295,720



    Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented.

     

    PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

    RECONCILIATION OF GAAP TO NON-GAP FINANCIAL MEASURES

    ADJUSTED EBITDA







    Three Months

    Ended June 30,





    Fiscal Year

    Ended June 30,





    2023





    2022





    2023





    2022

    Net loss (GAAP)



    $

    (96,125)





    $

    (113,899)





    $

    (144,613)





    $

    (928,418)

































    Stock based compensation





    149,242







    231,115







    919,032







    915,494

































    Depreciation and amortization





    53,275







    66,207







    210,735







    190,068

































    Interest expense





    51,484







    52,778







    218,927







    159,538

































    State Income Taxes





    1,936







    952







    1,936







    952

































    Acquisition Expense





    –







    –







    –







    162,125

































    Revaluation of earn-out liability





    (571,838)







    –







    (714,798)







    (742,052)

































    Adjusted EBITDA (non-GAAP)



    $

    (412,026)





    $

    237,153





    $

    491,219





    $

    (242,293)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-optics-reports-fourth-quarter-and-fiscal-year-2023-financial-results-301942298.html

    SOURCE Precision Optics Corporation

    Get the next $POCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

      SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      11/13/24 5:53:45 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Precision Optics Corporation Inc.

      SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      5/17/24 5:03:18 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:31 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:30 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:33 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results

      GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its third quarter fiscal year 2025 for the period ended March 31, 2025. Q3 2025 Financial Highlights (3 Months Ended March 31, 2025): Revenue was $4.2 million compared to $5.2 million in the same quarter of the previous fiscal year and compared to $4.5 million in the most recent sequential quarter.Production revenue was $3.3 million compared to $3.0 million in the same quarter of the previous fiscal year and compared to $

      5/15/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

      GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapCl

      4/21/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

      GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

      3/4/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

      GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

      7/8/24 9:00:00 AM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woodward Peter H exercised 30,000 shares at a strike of $2.19 and covered exercise/tax liability with 14,536 shares (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      5/20/25 4:15:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Pellegrino Joseph P Jr

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:17:04 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman was granted 20,000 shares, increasing direct ownership by 16% to 142,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:15:13 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    SEC Filings

    See more
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/23/25 4:40:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/20/25 4:15:10 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/19/25 4:30:09 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Financials

    Live finance-specific insights

    See more
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Second Quarter of Fiscal Year 2025 Conference Call for February 13, 2025

      GARDNER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, February 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, February 13, 2025, at 5:00 p.m. ET. Call-in Information: Inter

      2/11/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024

      GARDNER, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2025 financial results on Thursday, November 14, 2024, at 5:00pm ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 14, 2024, followed by the conference call. Conference Call Details Date and Time: Thursday, November 14, 2024, at 5:00pm ET Call-in Information: Interested pa

      11/11/24 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care